Data2Discovery P3 technologies identify potential new drugs for Tuberculosis

Tuberculosis (TB) is a major world health concern, being a declared global emergency and the second most common cause of death from infectious disease globally. In an innovative partnership with the NIH National Center for Advancing Translational Sciences (NCATS), and the OpenPHACTS foundation in the U.K., Data2Discovery Inc has applied its P3 graph-based association finding approach to identify 14 potential drug repurposing opportunities for TB. This small-scale project successfully demonstrated the feasibility of combining two key data resources – EU OpenPHACTS Open Pharmacological Space (OPS) and NCATS Phenotypic Drug Discovery Resource (PDDR) – with state of the art graph mining tools from Data2Discovery. "This proof-of-concept project indicates that a radical new approach to understanding disease and treatment strategies can be highly fruitful", said Dr. David Wild, Founder & President of Data2Discovery. The capabilities demonstrated in this project opens up many opportunities for public impact in rare and neglected diseases, as well as complex disease areas being pursued by pharmaceutical companies.